Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer

Inclusion Criteria:

* Female gender
* 18 years or older
* Performance Status- ECOG: 0-1
* Histologically confirmed invasive breast cancer
* Primary tumor greater than 2 cm diameter
* Any N (0-3)
* No evidence of metastasis (M0), HER-2/ERBb2 negative.
* Known hormone receptors status.
* Haematopoietic status: Absolute neutrophil count \> 1.5 x 109/L; Platelet count \> 100 x 109/L
* Hemoglobin at least 9 g/dl)
* Hepatic status: Serum total bilirubin \< 1.5 x upper limit of normal (ULN), in the case of known Gilbert's syndrome, a higher serum total bilirubin (\< 2 x ULN) is allowed;AST and ALT \< 2.5 times ULN; Alkaline phosphatase \< 2.5 times ULN)
* Renal status: Creatinine \< 1.5 mg/dl or Cl CR \> 60 ml/m
* For women of childbearing potential Negative serum pregnancy test, within 2-weeks (preferably 7 days) prior to randomization.
* Signed informed consent form (ICF).

Exclusion Criteria:

* Received any prior treatment for primary invasive breast cancer.
* Previous (less than 10 years) or current history of malignant neoplasms, except for curatively treated:
* Basal and squamous cell carcinoma of the skin;Carcinoma in situ of the cervix.
* Diagnosis of inflammatory breast cancer.
* Known history of uncontrolled or symptomatic angina, clinically significant arrhythmias, congestive heart failure, transmural myocardial infarction uncontrolled hypertension (? 180/110), unstable diabetes mellitus, dyspnoea at rest, or chronic therapy with oxygen.
* Left Ventricular Ejection Fraction of \< 50% measured by echocardiography.
* Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject?s safety.
* Unresolved or unstable, serious adverse events from prior administration of another investigational drug.
* Active or uncontrolled infection.
* Dementia, altered mental status, or any psychiatric condition that would prevent the understanding or rendering of ICF.
* Concurrent neoadjuvant cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy other than the trial therapies).
* Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial.
* Known immediate or delayed hypersensitivity reaction, idiosyncrasy or contraindication to drugs chemically related to any of the study treatments or their excipients.
* Pregnant or lactating women.
* Refusal to use contraception throughout the study (surgical sterilization, barrier methods associated with spermicidal gels or total abstinence). Use of hormonal contraceptives is not allowed.
* Patient unable to comply with study procedures.